PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Use of Specialized Coagulation Testing in the Evaluation of Patients with Acute Ischemic Stroke
Neurol 56:624-627, Bushnell,C.,et al, 2001
Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke
Stroke 31:3067-3078, Bushnell,C.D. & Goldstein,L.B., 2000
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
Rapid Diagnosis of Bacterial Meningitis with Reagent Strips
Lancet 345:1290-1291, Moosa,A.A.,et al, 1995